Thursday, September 24Thursday, 24 September 2026 - EST (Eastern Time, UTC-05:00

Exploring the application of transformer-based language models to mRNA design, demonstrating how AI can accelerate the optimization of codon sequences for improved vaccine and therapeutic performance.

Development of stabilized nanoparticle formulations designed to enable multiple routes of mRNA delivery beyond traditional intravenous administration, including inhaled, topical, and other localized delivery methods to expand therapeutic applications.

Engineering nanoparticle platforms with enhanced stability and tissue-specific targeting capabilities, allowing mRNA therapeutics to be delivered directly to disease sites through diverse administration routes while maintaining cargo integrity.

Development of tissue-specific lipid nanoparticle (LNP) formulations engineered to selectively deliver mRNA therapeutics to muscle tissue, bone marrow, and immune cells, utilizing targeted delivery strategies to enhance therapeutic efficacy and reduce systemic exposure

Lipid nanoparticles are at the heart of nanomedicine development, but moving from early formulation screening to a production-ready process can be time consuming, sample-hungry and operationally complex. In this talk, we’ll explore the evolving LNP synthesis needs across the nanomedicine development journey and show how the combination of Sunny Suite and Stunner from Unchained Labs helps teams step up their nanoparticle game. From low-volume, automated screening that conserves precious reagents, to high-throughput characterization that provides encapsulation efficiency at the same time as sizing, join us to see how the right tools can simplify development, accelerate iteration and help turn promising nanoparticle ideas into real therapeutic progress.